Ghassan Dbaibo

Prof. Dr. Ghassan Dbaibo

orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2003 in Endocrinology
Verified
Journal Article
Closed access
WEWissal El-Assaad
Wissal El-Assaad
JBJean Buteau
Jean Buteau
MPMarie-Line Peyot
Marie-Line Peyot
CNChristopher Nolan
Christopher Nolan
Raphael RoduitRaphael Roduit
Raphael Roduit
MPMarc Prentki
Marc Prentki
We have proposed the "glucolipotoxicity" hypothesis in which elevated free fatty acids (FFAs) together with hyperglycemia are synergistic in causing islet beta-cell damage because high glucose inhibits fat oxidation and consequently lipid detoxification. The effects of 1-2 d culture of both rat INS 832/13 cells and human islet beta-cells were investigated in medium containing glucose (5, 11, 20 mM) in the presence or absence of various FFAs. A marked synergistic effect of elevated concentrations of glucose and saturated FFA (palmitate and stearate) on inducing beta-cell death by apoptosis was found in both INS 832/13 and human islet beta-cells. In comparison, linoleate (polyunsaturated) synergized only modestly with high glucose, whereas oleate (monounsaturated) was not toxic. Treating cells with the acyl-coenzyme A synthase inhibitor triacsin C, or the AMP kinase activators metformin and 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside that redirect lipid partitioning to oxidation, curtailed glucolipotoxicity. In contrast, the fat oxidation inhibitor etomoxir, like glucose, markedly enhanced palmitate-induced cell death. The data indicate that FFAs must be metabolized to long chain fatty acyl-CoA to exert toxicity, the effect of which can be reduced by activating fatty acid oxidation. The results support the glucolipotoxicity hypothesis of beta-cell failure proposing that elevated FFAs are particularly toxic in the context of hyperglycemia.

1 September 1995 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
JWJohn K. Westwick
John K. Westwick
ABAlicja E. Bielawska
Alicja E. Bielawska
Ghassan DbaiboGhassan Dbaibo
Ghassan Dbaibo
YHYusuf A. Hannun
Yusuf A. Hannun
DBDavid Allen Brenner
David Allen Brenner
Tumor necrosis factor α (TNFα) activates the stress-activated protein kinases (SAPKs, also known as Jun nuclear kinases or JNKs) resulting in the stimulation of AP-1-dependent gene transcription and induces the translocation of NFκB to the nucleus resulting in the stimulation of NFκB-dependent gene transcription. A potential second messenger for these signaling pathways is ceramide, which is generated when TNFα activates sphingomyelinases. We show that treatment of HL-60 human promyelocytic cells with exogenous sphingomyelinase leads to rapid stimulation of JNK/SAPK activity, an effect not mimicked by treatment with phospholipase A, C, or D. Further, JNK/SAPK activity is stimulated 2.7- and 2.8-fold, respectively, in cells exposed to C-ceramide (5 μM) or TNFα (10 ng/ml). The prolonged stimulation of this kinase activity by C-ceramide is similar to that previously reported for TNFα. In contrast, the related mitogen-activated protein kinases ERK1 and ERK2 are weakly stimulated following TNFα treatment (1.5-fold) and are inhibited by C-ceramide treatment. TNFα also potently stimulates NF-κB DNA binding activity and transcriptional activity, but these effects are not mimicked by addition of C-ceramide or sphingomyelinase to intact cells. Furthermore, TNFα, sphingomyelinase, and C-ceramide induce c-jun, a gene that is stimulated by the ATF-2 and c-Jun transcription factors. These data suggest that ceramide may act as a second messenger for a subset of TNFα's biochemical and biological effects.

1 January 2015 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
LCLouis-Marie Charbonnier
Louis-Marie Charbonnier
EJErin Janssen
Erin Janssen
JCJanet Chou
Janet Chou
TOToshiro K. Ohsumi
Toshiro K. Ohsumi
SKSevgi Keles
Sevgi Keles
TCTalal A. Chatila
Talal A. Chatila

13 May 2012 in Nature Immunology
Verified
Journal Article
Open access
PDF file
HJHaifa H Jabara
Haifa H Jabara
DMDouglas R McDonald
Douglas R McDonald
EJErin Janssen
Erin Janssen
MMMichel J Massaad
Michel J Massaad
NRNarayanaswamy Ramesh
Narayanaswamy Ramesh
RGRaif S Geha
Raif S Geha
Dock8 deficiency leads to defects in humoral immunity. Geha and colleagues show that Dock88 interacts with MyD88 to bridge TLR9 signaling to the Src-Syk-STAT3 pathway to promote B cell proliferation and differentiation. The adaptors DOCK8 and MyD88 have been linked to serological memory. Here we report that DOCK8-deficient patients had impaired antibody responses and considerably fewer CD27+ memory B cells. B cell proliferation and immunoglobulin production driven by Toll-like receptor 9 (TLR9) were considerably lower in DOCK8-deficient B cells, but those driven by the costimulatory molecule CD40 were not. In contrast, TLR9-driven expression of AICDA (which encodes the cytidine deaminase AID), the immunoglobulin receptor CD23 and the costimulatory molecule CD86 and activation of the transcription factor NF-κB, the kinase p38 and the GTPase Rac1 were intact. DOCK8 associated constitutively with MyD88 and the tyrosine kinase Pyk2 in normal B cells. After ligation of TLR9, DOCK8 became tyrosine-phosphorylated by Pyk2, bound the Src-family kinase Lyn and linked TLR9 to a Src–kinase Syk–transcription factor STAT3 cascade essential for TLR9-driven B cell proliferation and differentiation. Thus, DOCK8 functions as an adaptor in a TLR9-MyD88 signaling pathway in B cells.

12 October 2015 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
JWJolan E. Walter
Jolan E. Walter
LRLindsey B. Rosen
Lindsey B. Rosen
KCKrisztian Csomos
Krisztian Csomos
JRJacob M. Rosenberg
Jacob M. Rosenberg
DMDivij Mathew
Divij Mathew
LNLuigi Daniele Notarangelo
Luigi Daniele Notarangelo
Patients with mutations of the recombination-activating genes (RAG) present with diverse clinical phenotypes, including severe combined immune deficiency (SCID), autoimmunity, and inflammation. However, the incidence and extent of immune dysregulation in RAG-dependent immunodeficiency have not been studied in detail. Here, we have demonstrated that patients with hypomorphic RAG mutations, especially those with delayed-onset combined immune deficiency and granulomatous/autoimmune manifestations (CID-G/AI), produce a broad spectrum of autoantibodies. Neutralizing anti–IFN-α or anti–IFN-ω antibodies were present at detectable levels in patients with CID-G/AI who had a history of severe viral infections. As this autoantibody profile is not observed in a wide range of other primary immunodeficiencies, we hypothesized that recurrent or chronic viral infections may precipitate or aggravate immune dysregulation in RAG-deficient hosts. We repeatedly challenged Rag1S723C/S723C mice, which serve as a model of leaky SCID, with agonists of the virus-recognizing receptors TLR3/MDA5, TLR7/-8, and TLR9 and found that this treatment elicits autoantibody production. Altogether, our data demonstrate that immune dysregulation is an integral aspect of RAG-associated immunodeficiency and indicate that environmental triggers may modulate the phenotypic expression of autoimmune manifestations.

1 March 2006 in Human Mutation
Verified
Journal Article
Open access
PDF file
Georges NemerGeorges Nemer
Georges Nemer
FFFatimah Fadlalah
Fatimah Fadlalah
JUJulnar Usta
Julnar Usta
MNMona Nemer
Mona Nemer
Ghassan DbaiboGhassan Dbaibo
Ghassan Dbaibo
FBFadi Bitar
Fadi Bitar
In vertebrates, heart formation which integrates different structures and cell types is a complex process that involves a network of genes regulated by transcription factors. Proper spatiotemporal expression of these factors ensure the highly needed tight control of each step in organogenesis. A mistake at any step from cell-commitment to valve formation will have a major impact on heart morphogenesis and function leading to congenital heart disease (CHD). Cardiac abnormalities occur with an incidence of one per 100 live births and represent 25% of all congenital malformations. As an alternative approach to linkage-analysis of familial cases of CHD, we started screening familial and sporadic cases of CHDs in a highly consanguineous population for mutations in genes encoding cardiac-enriched transcription factors. The evolutionarily conserved role of these proteins in cardiac development suggested a role in CHD. In this study, we report a mutation in the gene encoding GATA4, one of the earliest markers of heart development. This mutation was found in two out of 26 patients with Tetralogy of Fallot (TOF), and in none of the 94 patients with different phenotypes included in the study, nor in 223 healthy individuals. The heterozygous mutation results in an amino acid substitution in the first zinc finger of GATA4 that reduced its transcriptional activation of downstream target genes, without affecting GATA4 ability to bind DNA, nor its interaction with ZFPM2.